Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06003751 · ClinicalTrials.gov registry record · Phase 2
A Study of PER-001 in Participants With Diabetic Retinopathy
A Phase 2 study of Diabetic Retinopathy, sponsored by Perfuse Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06003751: Active Phase 2 study of Diabetic Retinopathy, sponsored by Perfuse Therapeutics.
NCT06003751 is a Phase 2 study of Diabetic Retinopathy that is active but no longer recruiting, run by Perfuse Therapeutics. The registered enrollment target is 24 participants, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06003751, a Phase 2 study of Diabetic Retinopathy, is active but no longer recruiting, sponsored by Perfuse Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2a, randomized, single-masked (participant), sham controlled clinical study.
Primary Outcome
Change in BCVA from Baseline at Week 24 using BETDRS or modified ETDRS chart (Charts 1, 2, and R as applicable) with standardized distance and lighting ill be used to calculate the LogMAR score
Conditions Studied
Interventions
- DRUG PER-001 Intravitreal Implant - Low Dose
- DRUG PER-001 Intravitreal Implant - High Dose
- DRUG PER-001 Intravitreal Implant - Sham
Study Locations (1)
California
- Perfuse Therapeutics, Inc - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-08-05 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
What the registry record for NCT06003751 still lists
NCT06003751 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 3 interventions - of which PER-001 Intravitreal Implant - Low Dose is the first listed.
NCT06003751 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06003751 about?
NCT06003751 is a clinical study titled "A Study of PER-001 in Participants With Diabetic Retinopathy". This is a Phase 2a, randomized, single-masked (participant), sham controlled clinical study.
What is the current status of trial NCT06003751?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2023-08-05. Estimated completion is 2026-04.
What conditions does trial NCT06003751 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT06003751?
The interventions under investigation include: PER-001 Intravitreal Implant - Low Dose (DRUG), PER-001 Intravitreal Implant - High Dose (DRUG), PER-001 Intravitreal Implant - Sham (DRUG).
Who is sponsoring clinical trial NCT06003751?
This trial is sponsored by Perfuse Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06003751 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06003751's enrollment target sits among peer trials
24 48th of 57 higher than 10 of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
RECRUITING · Phase 2
-
Sleep, Diabetic Retinopathy and Melatonin
RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
COMPLETED · Phase 2
-
Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI